Recombinant SIVgp160 does not induce protective immunity against experimental infection of rhesus macaques with SIV. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Recombinant SIVgp160 does not induce protective immunity against experimental infection of rhesus macaques with SIV.

Symp Nonhum Primate Models AIDS. 1992 Nov 17-20;10:abstract no. 133. Unique Identifier : AIDSLINE PRIM10/93200975
Yilma T; Ahmad S; Giavedoni L; el-Amad Z; Scandella C; Haigwood N; Marthas M; Gardner M; Luciw P; University of California, Davis 95616.

Abstract: Simian immunodeficiency virus (SIV) infection of rhesus macaques is a model for human immunodeficiency virus (HIV) in humans. Inactivated and modified live, whole-virus vaccines have provided limited protective immunity against SIV in rhesus macaques. Because of safety concerns in the use of inactivated or live, whole virus vaccines, we have evaluated envelope glycoproteins (gp160) expressed by recombinant vaccinia virus (vSIVgp160) and/or baculovirus (bSIVgp160) as subunit vaccines. All groups of animals received a primary and two booster immunizations. One group (8 animals) was vaccinated with vSIVgp160 and then boosted with bSIVgp160. A second group (4 animals) was immunized and boosted with vSIVgp160. A third group (4 animals) was immunized and boosted with bSIVgp160. In addition, a negative control (two animals) was vaccinated with wild-type vaccinia virus while a group of three animals was immunized with inactivated SIVmac251 for a positive control. All animals received their last booster immunization 32 weeks after primary immunization and two weeks before challenge. Four animals in the first group (vSIVgp160 + bSIVgp160) were challenged with 1-10 100% animal infectious dose of SIVmac239 (molecular clone) and the remaining with SIVmac251, both propagated in rhesus PBLS. Although anti-gp160 binding antibodies were elicited in all three groups immunized with preparations containing gp160, neutralizing antibodies were undetectable with the exception of the group vaccinated with inactivated virus. None of the immunized animals including the control groups resisted intravenous challenge. Previously, it has been demonstrated that inactivated virus vaccines provided protection against challenge with virus propagated in human PBLS, and this may be related to immune responses to cellular antigens. The results of these studies suggest that immunization with HIV-1 surface glycoprotein may not necessarily provide protective immunity against virus infection.
Keywords: Animal Gene Products, env/*IMMUNOLOGY Immunization, Secondary Macaca mulatta Recombinant Proteins/IMMUNOLOGY Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/PREVENTION & CONTROL SIV/*IMMUNOLOGY Time Factors Vaccines, Synthetic/*IMMUNOLOGY Vaccinia Virus/IMMUNOLOGY Viral Vaccines/*IMMUNOLOGY ABSTRACTKWDanimalgeneproducts,env/KWDimmunologyimmunization,secondarymacacamulattarecombinantproteins/immunologysimianacquiredimmunodeficiencysyndrome/KWDimmunology/prevention&controlsiv/KWDimmunologytimefactorsvaccines,synthetic/KWDimmunologyvacciniavirus/immunologyviralvaccines/KWDimmunologyabstract
930630
M9361045

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .